GLP-1RAs such as liraglutide and exenatide decrease pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-α), and interleukin-1β (IL-18) in rodent mouse models of diabetic neuropathy [69,70]. Here, TNF is linked to diabetic neuropathy.